Monday, September 25, 2017
Indivumed and Helomics announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.
PSI CRO has announced opening offices in Taiwan, listed as Taiwan PSI Health Development Co. Ltd. in Taipei.
Houston-based CRO MedSource is growing its service-offering to include the early stages of clinical development and pipeline planning through Investigational New Drug (IND) submissions. The service, rarely offered by CROs, will be provided by a new department—Scientific Development—which will be responsible for delivering a suite of clinical development services to biotech and pharmaceutical companies wishing to organize their pipeline strategy, prioritize indications, and develop strategies that will efficiently advance new drug candidates into the clinic. The enhanced offering establishes MedSource as a partner that can offer its expertise throughout the entire drug development process, in complement to the execution of clinical trials that has been a mainstay for its 20-year history.
Contract development and manufacturing organization (CDMO) Recipharm and CRO Clinical Trial Consultants (CTC) have partnered to launch a new service that delivers a clear, streamlined pathway to first in human milestones.
Parexel International, a global biopharmaceutical services provider, has launched a new end-to-end service offering to provide real-world data insights that help life science companies more effectively demonstrate product value.
Therapure Biopharma announced that a joint venture between 3SBio, a global biotechnology company, and CPE Funds (investment funds advised by CITICPE) has entered into an agreement to acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market for $290 million, subject to certain adjustments.
Biotech innovation hub LabCentral has signed Science Exchange, a secure platform for outsourced research and development (R&D), as a sponsor to support its life science and biotech resident startups. Companies within LabCentral’s shared workspaces are now able to order R&D services instantly via a customized Science Exchanged-powered marketplace, with access to more than 2,500 qualified scientific service providers.